GlassScriptPhysician profile
Allison P Rathan
NPI 1467447862
$2,607.44
in general payments reported to CMS, 2019-2025
9 companies · $535 in 2025
The $535 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2021: $248 · 2022: $316 · 2023: $496 · 2024: $527 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,558.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $808.70 | 2019-2025 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $487.97 | 2019-2024 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $372.10 | 2019-2025 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $272.57 | 2024-2025 | Arexvy, Shingrix, Nucala |
| Merck Sharp & Dohme LLC | $249.91 | 2023-2024 | Verquvo |
| Medtronic, INC. | $152.21 | 2024 | Symplicity G3 |
| Lilly USA, LLC | $125.00 | 2023 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $119.74 | 2019 | |
| Exact Sciences Corporation | $19.24 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Rathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.